The cure of cancer is not the only goal on the table and the very best are antibody-drug conjugates. These innovative drugs combine monoclonal antibodies with cytotoxic chemotherapies to deliver highly targetedRead More…
In a new study, researchers from Yale School of Medicine hide tumor-fighting antibodies from cancer by disguising them in molecules that cancers use to nourish tumor growth, based on a new therapyRead More…
Researchers from the University of Basel in Switzerland published a research paper titled “Selective haematological cancer eradication with preserved haematopoiesis” in the journal Nature. The entire hematopoietic system can be reconstructed byRead More…
The emergence of antibody-drug conjugates (ADCs) as a potential cancer treatment pathway has attracted a great deal of attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drugRead More…
Conditionally activated antibody prodrug conjugate (PDC) Traditional ADCs not only target receptors expressed on tumor cells but also those on certain healthy tissues, leading to inevitable off-tumor toxicity. Probody Drug Conjugates (PDCs)Read More…
Antibody-drug conjugates (ADCs) represent a highly promising approach to cancer treatment, capable of selectively delivering highly cytotoxic payloads to tumors. However, ADCs are currently facing a series of challenges, including resistance, tumorRead More…
Introduction of the Camptothecin Derivative Payload Camptothecin was first isolated from camptothecin stems in 1966 by Wall et al., mainly in the form of topological isomerase (topoI). In order to inhibit theRead More…
The popularity of sulfhydryl groups in ADC preparation can be traced back to three factors: (a) thiols are the most nucleophilic amino acid side-chain functional group (much more nucleophilic than amines); (b)Read More…
Antibody-drug conjugates (ADCs) comprise an antibody, a linker, and a cytotoxic active payload. Compared to traditional chemotherapy, ADCs that target tumors are expected to mitigate systemic toxic effects, provide a wider therapeuticRead More…
Antigen Target Selection A major challenge in developing antibody-drug conjugates (ADCs) for cancer lies in the identification and validation of sufficient antigen targets for the monoclonal antibody component. Several factors need toRead More…